Verubecestat (BACE1 inhibitor) Phase III EPOCH trial in mild-moderate AD halted for futility; cognitive worsening signal observed. Production-side amyloid intervention failed alongside MAb clearance approaches, narrowing therapeutic-window viability of the amyloid hypothesis.

Evidence span

Verubecestat (BACE1 inhibitor) Phase III EPOCH trial in mild-moderate AD halted for futility; cognitive worsening signal observed. Production-side amyloid intervention failed alongside MAb clearance approaches, narrowing therapeutic-window viability of the amyloid hypothesis.

From Michael Egan et al. 2018, New England Journal of Medicine

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Human, mild-moderate AD; verubecestat oral BACE1 inhibitor vs placebo; n=1958. Halted ~22 months post-randomization. NCT01739348.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required